- Charles River Laboratories Announces Opening of U.K. Manufacturing Facility
- Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
- Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
- Charles River Laboratories to Participate in Jefferies and William Blair Conferences
- Charles River Laboratories Announces First-Quarter 2022 Results
- Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
- Charles River Laboratories Schedules First-Quarter 2022 Earnings Release and Conference Call
- Charles River Laboratories Publishes 2021 Corporate Citizenship Report
- Charles River Laboratories Acquires Explora BioLabs
More ▼
Key statistics
As of last trade Charles River Laboratories International Inc (CRL:NYQ) traded at 220.01, 8.18% above its 52-week low of 203.37, set on Jun 14, 2022.
52-week range
Markit short selling activity
Open | 225.86 |
---|---|
High | 226.89 |
Low | 219.84 |
Bid | 219.98 |
Offer | 220.13 |
Previous close | 225.49 |
Average volume | 499.30k |
---|---|
Shares outstanding | 50.80m |
Free float | 50.29m |
P/E (TTM) | 27.48 |
Market cap | 11.46bn USD |
EPS (TTM) | 8.21 USD |
Data delayed at least 15 minutes, as of Jun 28 2022 17:33 BST.
More ▼